Bershad S V
Dermatology, The Mount Sinai School of Medicine, New York, NY, USA.
Mt Sinai J Med. 2001 Sep-Oct;68(4-5):279-86.
This review of current acne treatments begins with the crucial discovery in 1979 of isotretinoin treatment for nodulocystic acne. This drug s approval in 1982 revolutionized therapy, since it was the first oral acne-specific drug, and it provided prolonged remissions. In addition, it may prevent the emergence of resistant bacteria, a problem linked to the traditional use of antibiotics for acne. Patients who are not candidates for isotretinoin therapy may benefit from one of the other drugs or drug combinations reviewed, including the third-generation topical retinoids adapalene and tazarotene, retinoic acid reformulated in new vehicles, azelaic acid, and topical antibiotics. Proper selection and education of patients are essential, since serious consequences may result from poorly monitored use of antibiotics and retinoid.
本次对当前痤疮治疗方法的综述始于1979年异维A酸治疗结节囊肿性痤疮这一关键发现。该药物于1982年获批,彻底改变了痤疮治疗方式,因为它是第一种口服的专治痤疮的药物,且能带来长期缓解。此外,它可能预防耐药菌的出现,这是传统使用抗生素治疗痤疮所带来的一个问题。不适合使用异维A酸治疗的患者可能会从本文所综述的其他药物或药物组合中获益,包括第三代外用维甲酸类药物阿达帕林和他扎罗汀、以新剂型重新配制的维甲酸、壬二酸以及外用抗生素。对患者进行正确的选择和教育至关重要,因为抗生素和维甲酸使用监测不当可能会导致严重后果。